| IEX |
Report |
2Q26 adjusted diluted EPS |
BEAT |
pred ~$2.15 vs. cons $2.11 |
MEDIUM |
| IEX |
Report |
2Q26 organic sales growth |
BEAT |
pred ~4.3% vs. cons 3.6% |
MEDIUM |
| IEX |
Report |
2Q26 adjusted EBITDA margin |
IN-LINE |
pred ~26.9% vs. cons 26.8% |
MEDIUM |
| IEX |
Guide |
FY26 organic sales growth |
BETTER |
guide ~4.0% midpoint vs. cons 3.6% (FY26) |
MEDIUM |
| IEX |
Guide |
FY26 adjusted diluted EPS |
BETTER |
guide ~$8.55 midpoint vs. cons $8.50 (FY26) |
MEDIUM |
| IEX |
Guide |
FY26 adjusted EBITDA margin |
UNCHANGED |
guide ~26.75% midpoint vs. cons 26.8% (FY26) |
HIGH |
| IEX |
Guide |
FY26 free-cash-flow conversion |
UNCHANGED |
guide ~100% vs. cons 100% (FY26) |
HIGH |
| IEX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| IEX |
Return |
5-day cumulative residual |
+3.5% (FOLLOW-THROUGH) |
Day 1 residual ~2.5% and day 5 residual ~3.5%: an EPS/organic-growth beat paired with a ~4.0% FY26 organic-growth midpoint and ~$8.55 FY26 EPS midpoint supports modest upward revisions to the out-period earnings base rather than a one-quarter-only beat. |
MEDIUM |